OncoMed to Present at Two Upcoming Investor Conferences in September
August 29, 2018 16:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial
September 13, 2017 08:05 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
March 08, 2017 16:05 ET
|
OncoMed Pharmaceuticals, Inc.
Demcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017 Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30...
OncoMed Announces Year-End Cash Balance and 2017 Outlook
January 05, 2017 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
Enters 2017 with $184.6 Million in Cash Potential for Five Program Opt-ins Totaling Over $170M Anti-TIGIT (I/O#2) IND Filed REDWOOD CITY, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- OncoMed...
OncoMed Pharmaceuticals Reports Third Quarter 2016 Financial Results
November 01, 2016 16:05 ET
|
OncoMed Pharmaceuticals, Inc.
Ends Quarter with $207 Million Cash Enrollment Complete in Phase 2 Trials for Demcizumab and Tarextumab;On Track for Data in 1H 2017 OncoMed Management to Host Conference Call/Webcast this...
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
September 01, 2016 08:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 PINNACLE Clinical Trial of Tarextumab in Small Cell Lung Cancer
August 30, 2016 08:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
May 05, 2016 16:04 ET
|
OncoMed Pharmaceuticals, Inc.
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT Highlights AACR Presentations - Including Novel GITRL-Fc Candidate Clinical Data on Vantictumab,...
OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016
March 16, 2016 16:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and...
OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium
January 22, 2016 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 22, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...